Correlation between serum secreted frizzled-related protein 5 and early renal damage in patients with essential hypertension

doi:10.3969/j.issn.1004-583X.2023.12.003

Abstract

Abstract:

Objective To investigate the correlation between serum secreted frizzled-related protein 5 (SFRP5) and early renal damage in patients with essential hypertension. Methods During January 2017 to December 2017, a total of 88 patients who were initially diagnosed as essential hypertension in the Second Hospital of Hebei Medical University were recruited, and they were divided into group B (UACR<30 mg/g, $n$ =41) and group C (30 mg/g≤UACR≤300 mg/g, $n$ =47) based on the urine albumin creatine ratio (UACR). During the same period, 32 healthy volunteers receiving physical examinations were included in group A. Serum SFRP5, cystatin C (Cys-C), blood urea nitrogen and serum creatinine were compared. Results Serum SFRP5 was significantly lower in group C than that of group A and group B ( $P$ <0.01), which was significantly lower in group B than that of group A ( $P$ <0.05). Cys-C was significantly higher in group C than that of group A and group B ( $P$ <0.01). SFRP5 was negatively correlated with UACR ( $r$ =-0.839, $P$ <0.01) and Cys-C ( $r$ =-0.378, $P$ <0.05). Cys-C was positively correlated with UACR ( $r$ =0.625, $P$ <0.01). SFRP5 was an independent protective factor for hypertensive renal damage (β=-0.036, $P$ <0.01), and Cys-C was an independent risk factor for it (β=0.288, $P$ <0.01). Conclusion SFRP5 may be a protective factor for renal damage in hypertension, serving as a potential predictive and therapeutic target for it. Our findings provide a new direction for clinical medication and evaluation of drug efficacy.

Key words: hypertension, early renal damage, secreted frizzled-related protein 5 (SFRP5), cystatin C (Cys-C), urinary albumin/creatinine ratio

CLC Number:

R544.1

Liu Yi, Cui Kun, Liu Chang, Zhao Haotian, Li Li, Xue Hongyuan. Correlation between serum secreted frizzled-related protein 5 and early renal damage in patients with essential hypertension[J]. Clinical Focus, 2023, 38(12): 1073-1077.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.12.003

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I12/1073

Figures/Tables 6

Tab.1 Comparison of clinical characteristics in the three groups

组别		例数	年龄(岁)		性别[例(%)]			吸烟[例(%)]				BMI(kg/m²)		BUN(mmol/L)
组别		例数	年龄(岁)		男		女	是		否		BMI(kg/m²)		BUN(mmol/L)
A组		32	65.42±5.46		18(56.3)		14(43.7)	11(34.4)		21(65.6)		24.03±1.22		7.04±2.11
B组		41	65.83±6.31		24(58.5)		17(41.5)	14(34.1)		27(65.9)		25.54±1.41		7.35±1.80
C组		47	66.39±5.97		28(59.6)		19(40.4)	16(34.0)		31(66.0)		25.39±1.03		7.62±2.07
$P$ 值			0.551		0.521			0.630				0.211		0.482
组别	SCr(μmol/L)			TC(mmol/L)		TG(mmol/L)			LDL-C(mmol/L)		HDL-C(mmol/L)		FPG(mmol/L)
A组	87.82±11.43			4.26±0.35		1.29±0.18			2.90±0.78		1. 38±0.27		5.51±0.35
B组	89.62±10.51			4.55±0.67		1.40±0.45			2.98±0.83		1.29±0.75		5.63±0.49
C组	92.36±12.16			4.48±1.04		1.37±0.62			3.19±0.94		1.28±0.91		5.71±0.57
$P$ 值	0.110			0.431		0.452			0.140		0.162		0.264

Tab.1 Comparison of clinical characteristics in the three groups

组别		例数	年龄(岁)		性别[例(%)]			吸烟[例(%)]				BMI(kg/m²)		BUN(mmol/L)
组别		例数	年龄(岁)		男		女	是		否		BMI(kg/m²)		BUN(mmol/L)
A组		32	65.42±5.46		18(56.3)		14(43.7)	11(34.4)		21(65.6)		24.03±1.22		7.04±2.11
B组		41	65.83±6.31		24(58.5)		17(41.5)	14(34.1)		27(65.9)		25.54±1.41		7.35±1.80
C组		47	66.39±5.97		28(59.6)		19(40.4)	16(34.0)		31(66.0)		25.39±1.03		7.62±2.07
$P$ 值			0.551		0.521			0.630				0.211		0.482
组别	SCr(μmol/L)			TC(mmol/L)		TG(mmol/L)			LDL-C(mmol/L)		HDL-C(mmol/L)		FPG(mmol/L)
A组	87.82±11.43			4.26±0.35		1.29±0.18			2.90±0.78		1. 38±0.27		5.51±0.35
B组	89.62±10.51			4.55±0.67		1.40±0.45			2.98±0.83		1.29±0.75		5.63±0.49
C组	92.36±12.16			4.48±1.04		1.37±0.62			3.19±0.94		1.28±0.91		5.71±0.57
$P$ 值	0.110			0.431		0.452			0.140		0.162		0.264

Fig.1 Comparison of SFRP5 in the three groups

Tab.2 Comparison of SFRP5 and Cys-C levels in the three groups

组别	例数	SFRP5(ng/ml)	Cys-C(mg/L)
A组	32	19.27±2.83	0.86±0.11
B组	41	17.72±2.52^*	0.87±0.10
C组	47	7.20±2.79^*#	2.50±0.50^*#
$F$ 值		257.377	358.278
$P$ 值		<0.01	<0.01

Tab.2 Comparison of SFRP5 and Cys-C levels in the three groups

组别	例数	SFRP5(ng/ml)	Cys-C(mg/L)
A组	32	19.27±2.83	0.86±0.11
B组	41	17.72±2.52^*	0.87±0.10
C组	47	7.20±2.79^*#	2.50±0.50^*#
$F$ 值		257.377	358.278
$P$ 值		<0.01	<0.01

Fig.2 Correlation analysis of SFRP5, Cys-C and UACR in EH patients with early renal damage

Tab. 3 Correlation analysis between UACR and SFRP5, Cys-C in EH patients with early renal damage

自变量	$r$	$P$
SFRP5(ng/ml)	-0.839	<0.01
Cys-C(mg/L)	0.625	<0.01

Tab. 3 Correlation analysis between UACR and SFRP5, Cys-C in EH patients with early renal damage

自变量	$r$	$P$
SFRP5(ng/ml)	-0.839	<0.01
Cys-C(mg/L)	0.625	<0.01

Tab.4 Multiple Linear regression analysis

自变量	β	BE	beta	$t$ 值	$P$ 值
SFRP5	-0.036	0.007	-0.444	-5.255	<0.01
Cys-C	0.288	0.047	0.517	6.120	<0.01

Tab.4 Multiple Linear regression analysis

自变量	β	BE	beta	$t$ 值	$P$ 值
SFRP5	-0.036	0.007	-0.444	-5.255	<0.01
Cys-C	0.288	0.047	0.517	6.120	<0.01

References 21

[1]	中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1):24-56.
[2]	Mulè G, Castiglia A, Cusumano C, et al. Subclinical kidney damage in hypertensive patients: A renal window opened on the cardiovascular system. Focus on microalbuminuria[J]. Adv Exp Med Biol, 2017, 956:279-306. doi: 10.1007/5584_2016_85 pmid: 27873229
[3]	Ruiz-Hurtado G, Ruilope LM. Microvascular injury and the kidney in hypertension[J]. Hipertens Riesgo Vasc, 2018, 35(1):24-29. doi: S1889-1837(17)30021-1 pmid: 28431922
[4]	Xiao L, Harrison DG. Inflammation in hypertension[J]. Can J Cardiol, 2020, 36(5):635-647. doi: S0828-282X(20)30048-9 pmid: 32389337
[5]	Zhang Z, Zhao L, Zhou X, et al. Role of inflammation, immunity, and oxidative stress in hypertension: New insights and potential therapeutic targets[J]. Front Immunol, 2023, 13:1098725. doi: 10.3389/fimmu.2022.1098725 URL
[6]	Zhang RM, McNerney KP, Riek AE, et al. Immunity and hypertension[J]. Acta Physiol (Oxf), 2021, 231(1):e13487. doi: 10.1111/apha.2021.231.issue-1 URL
[7]	Girndt M. Diagnosis and treatment of chronic kidney disease[J]. Internist (Berl), 2017, 58(3):243-256. doi: 10.1007/s00108-017-0195-2 pmid: 28194476
[8]	Oz-Sig O, Kara O, Erdogan H. Microalbuminuria and serum cystatin C in prediction of early-renal insufficiency in children with obesity[J]. Indian J Pediatr, 2020, 87(12):1009-1013. doi: 10.1007/s12098-020-03294-z
[9]	Ekpenyong EE, Ikpeme EE, Bassey EG, et al. Early detection of renal injury in children with sickle cell anaemia using microalbuminuria in a tertiary health institution in southern nigeria[J]. West Afr J Med, 2020, 37(4):412-417. pmid: 32835405
[10]	Tsaryk I, Pashkovska N. The role of renal damage markers in the diagnosis of early stages of kidney injury in patients with latent autoimmune diabetes in adults[J]. J Med Life, 2022, 15(6):792-796. doi: 10.25122/jml-2022-0062 pmid: 35928354
[11]	Yin LH, Yan WJ, Guo ZX, et al. Relation between blood pressure variability and early renal damage in hypertensive patients[J]. Eur Rev Med Pharmacol Sci, 2017, 21(9):2226-2231.
[12]	Jung HN, Jung CH. The role of anti-Inflammatory adipokines in cardiometabolic disorders: Moving beyond adiponectin[J]. Int J Mol Sci, 2021, 22(24):13529. doi: 10.3390/ijms222413529 URL
[13]	Tong S, Du Y, Ji Q, et al. Expression of Sfrp5/Wnt5a in human epicardial adipose tissue and their relationship with coronary artery disease[J]. Life Sci, 2020, 245:117338. doi: 10.1016/j.lfs.2020.117338 URL
[14]	Zhang C, Fang X, Zhang H, et al. Genetic susceptibility of hypertension-induced kidney disease[J]. Physiol Rep, 2021, 9(1):e14688.
[15]	Roy JP, Devarajan P. Acute kidney injury: Diagnosis and management[J]. Indian J Pediatr, 2020, 87(8):600-607. doi: 10.1007/s12098-019-03096-y
[16]	郝永哲, 程文俊. 高血压早期肾损害的研究进展[J]. 中国医药导报, 2017, 14(27):56-61.
[17]	Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature[J]. Diab Vasc Dis Res, 2021, 18(6):14791641211058856.
[18]	Tong S, Ji Q, Du Y, et al. Sfrp5/Wnt pathway: A protective regulatory system in atherosclerotic cardiovascular disease[J]. J Interferon Cytokine Res, 2019, 39(8):472-482. doi: 10.1089/jir.2018.0154 URL
[19]	Carstensen-Kirberg M, Kannenberg JM, Huth C, et al. Inverse associations between serum levels of secreted frizzled-related protein-5 (SFRP5) and multiple cardiometabolic risk factors: KORA F4 study[J]. Cardiovasc Diabetol, 2017, 16(1):109. doi: 10.1186/s12933-017-0591-x pmid: 28851362
[20]	Wang D, Zhang Y, Shen C. Research update on the association between SFRP5, an anti-inflammatory adipokine, with obesity, type 2 diabetes mellitus and coronary heart disease[J]. J Cell Mol Med, 2020, 24(5):2730-2735. doi: 10.1111/jcmm.15023 pmid: 32004418
[21]	Bai Z, Li H, Li C, et al. Integrated analysis identifies a long non-coding RNAs-messenger RNAs signature for prediction of prognosis in hepatitis B virus-hepatocellular carcinoma patients[J]. Medicine (Baltimore), 2020, 99(40):e21503. doi: 10.1097/MD.0000000000021503 URL